Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28432522 | 0.88 | ALDH1A1 (0.57) | ALDH1A1MAPTPOLBHTTLMNA | |
| SCHEMBL5416311 | 0.83 | MAPT (0.57) | ALDH1A1MAPTPOLBHTTLMNA | |
| SCHEMBL10733902 | 0.82 | MAPT (0.56) | ALDH1A1MAPTPOLBHTTLMNA | |
| SCHEMBL10733909 | 0.82 | MAPT (0.60) | ALDH1A1MAPTPOLBHTTLMNA | |
| SCHEMBL11270696 | 0.80 | MAPT (0.53) | ALDH1A1MAPTPOLBLMNA | |
| SCHEMBL10920261 | 0.79 | MAPT (0.54) | ALDH1A1MAPTPOLBHTTLMNA | |
| SCHEMBL101951 | 0.78 | ALDH1A1 (0.41) | ALDH1A1MAPTPOLBHTTLMNA | |
| SCHEMBL27567012 | 0.77 | ALDH1A1 (0.39) | ALDH1A1MAPTPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL841946 | 0.76 | KDM4E (0.49) | ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL22574784 | 0.75 | ALDH1A1 (0.49) | ALDH1A1MAPTPOLBHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4526298-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. Hoffmann-La Roche AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-119212989-A | Pyrazole derivatives as STING agonists | 豪夫迈·罗氏有限公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023222644-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074913-A1 | PYRAZOLE DERIVATIVES AS STING AGONISTS | STING1, CGAS, MAVS | ALDH1A1 4593/4885MAPT 4128/4885POLB 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.